Skip to Content
Merck
All Photos(1)

Documents

Y0001034

Lynestrenol for peak identification

European Pharmacopoeia (EP) Reference Standard

Synonym(s):

Lynestrenol, (17α)-19-Norpregn-4-en-20-yn-17-ol

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C20H28O
CAS Number:
52-76-6
Molecular Weight:
284.44
UNSPSC Code:
41116107
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

lynestrenol

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

InChI

1S/C20H28O/c1-3-20(21)13-11-18-17-9-8-14-6-4-5-7-15(14)16(17)10-12-19(18,20)2/h1,6,15-18,21H,4-5,7-13H2,2H3/t15-,16+,17+,18-,19-,20-/m0/s1

InChI key

YNVGQYHLRCDXFQ-XGXHKTLJSA-N

Looking for similar products? Visit Product Comparison Guide

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Lynestrenol for peak identification EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Sanna Palovaara et al.
British journal of clinical pharmacology, 56(2), 232-237 (2003-08-05)
To study the effect of an oral contraceptive (OC) formulation containing ethinyloestradiol and levonorgestrel (LNG) (combination OC) or LNG alone on the CYP2C19-mediated hydroxylation of omeprazole in healthy females. This was an open crossover study with three phases. In phase
M Djangidze et al.
Georgian medical news, (151)(151), 26-31 (2007-12-12)
Background diseases of the cervix of the uterus play one of the leading roles in the structure of gynecological pathology and present the risk of the development precancerous changes. Ectopia is observed in the structure of precancerous processes of the
J Endrikat et al.
Contraception, 69(3), 179-187 (2004-02-19)
In this first prospective, double-blind, randomized, parallel-group study we evaluated the influence of two combined oral contraceptives on bone mineral density (BMD) and metabolic bone parameters. One dose-reduced preparation contained 20 microg ethinylestradiol (EE) in combination with 100 microg levonorgestrel
Eva-Katrin Bentz et al.
Fertility and sterility, 94(7), 2688-2696 (2010-06-12)
To evaluate gene expression signatures of breast tissue in female-to-male (FtM) transsexuals under cross-sex hormone therapy (HT). Prospective cohort study. Academic research institution. Five hormone-naïve FtM transsexuals before and after HT. Breast tissue biopsy before and after 2 years of
M Jangidze et al.
Georgian medical news, (141)(141), 21-26 (2007-01-31)
The aim of the study was the investigation of impact of different hormonal contraceptive drugs on cervix of uterus of young nullipara women with ectopia. Cytologic smears were examined using Pappanikolau method. Cohort study was carried out by using simple
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service